Print

A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/119/a-survey-on-options-for-managing-cancer-risk-among-women-with-a-brca1-or-brca2-mutation

Surveys, Registries, Interviews

Study Contact Information:

For more information, contact our study Coordinator:                           

Patricia Nguyen by phone 416-323-6400 Ext. 2761 or by email.


About the Study

Women with a BRCA1 or BRCA2 mutation are at higher risk of developing breast and/or ovarian cancer compared to women in the general population. There are various options available to these women to help reduce or manage these risks, including preventive surgery. We are conducting an important new study to examine and understand cancer prevention decisions and outcomes in these women.

This study is designed to investigate why women have chosen the cancer management options that they have, including what factors influence their decisions. This information will help in understanding why there are differences in uptake of cancer preventive or screening options and help improve the clinical care of this high-risk group.

Women interested in participating should contact our study coordinator Patricia Nguyen by phone 416-323-6400 Ext. 2761 or by email.

What the Study Entails

Participation is easy and requires the completion of a short, online, easy-to-use survey. The study survey collects demographic and medical information, and may require completion annually. This survey will require 15-20 minutes of your time. Upon completion of the survey, you will receive a gift card to thank you for your participation.

Lead Researchers

Dr. Joanne Kotsopoulos, PhD
Dr. Steven Narod, MD


This Study is Open To:

If you are interested in participating, you must meet the following eligibility criteria:

This Study is Not Open To:


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.